Shares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $27.19 and last traded at $27.74, with a volume of 124643 shares. The stock had previously closed at $29.00.
Analysts Set New Price Targets
IMCR has been the topic of several analyst reports. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a report on Wednesday. Morgan Stanley reiterated an "equal weight" rating and issued a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Immunocore has an average rating of "Moderate Buy" and an average price target of $65.64.
Get Our Latest Report on IMCR
Immunocore Stock Performance
The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.44 billion, a P/E ratio of -30.32 and a beta of 0.79. The company has a 50 day moving average price of $30.08 and a 200-day moving average price of $31.38.
Institutional Trading of Immunocore
Institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Immunocore in the fourth quarter valued at $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC lifted its holdings in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after purchasing an additional 1,102 shares during the last quarter. Tema Etfs LLC purchased a new stake in shares of Immunocore during the fourth quarter valued at $330,000. Finally, Virtus ETF Advisers LLC lifted its holdings in shares of Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after purchasing an additional 3,238 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.
Immunocore Company Profile
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Stories
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
